Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Authors: Cathy Eng, Tae Won Kim, Johanna C. Bendell, Guillem Argilés, Niall C. Tebbutt, Maria Di Bartolomeo, Alfredo Falcone, Marwan Fakih, Mark Kozloff, Neil H. Segal, Alberto Sobrero, Yibing Yan, Ilsung Chang, Anne Uyei, Louise Roberts, Fortunato Ciardiello, JB Ahn, Jamil Asselah, Suprith Badarinath, Shobhit Baijal, S. Begbie, Sneha Berry, J. R. Canon, RG Carbone, Andrés Cervantes, YJ Cha, Karen Chang, Arvind Chaudhry, Ewa Chmielowska, Seung‐Hun Cho, Derek K. Chu, Félix Couture, Jennifer L. Cultrera, David Cunningham, Eric Van Cutsem, P-J. Cuyle, Janine M. Davies, Scot Dowden, Mikhail Dvorkin, Vinod Ganju, RV Garcia, Rachel Kerr, Tae‐Yop Kim, Kevin G. King, Jeremy Kortmansky, Mark Kozloff, Ko Lam, J Lee, AS Lee, Bernard Lespérance, Gabriele Luppi, Boyu Ma, Evaristo Maiello, Romeo A. Mandanas, J. L. Marshall, Gavin Marx, Saifee Mullamitha, Marina Nechaeva, Jo Park, Nick Pavlakis, CG Ponce, Piotr Potemski, Sherif Raouf, James A. Reeves, Neil H. Segal, Salvatore Siena, Alexey Smolin, JO Streb, A. H. Strickland, Ewa Szutowicz-Zielińska, Josep Tabernero, Benjamin Tan, JS Valera, Marc Van den Eynde, Philippe Vergauwe, Michael M. Vickers, Mark Womack, Marta Wróblewska, Ruth T. Young - The Lancet 2019 cited by 562